Bryn Mawr Trust Advisors LLC Sells 9,389 Shares of Becton, Dickinson and Company $BDX

Bryn Mawr Trust Advisors LLC lowered its stake in Becton, Dickinson and Company (NYSE:BDX) by 19.3% in the 4th quarter, Holdings Channel reports. The firm owned 39,258 shares of the medical instruments supplier’s stock after selling 9,389 shares during the quarter. Bryn Mawr Trust Advisors LLC’s holdings in Becton, Dickinson and Company were worth $7,619,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in BDX. Brighton Jones LLC raised its holdings in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares in the last quarter. Oppenheimer Asset Management Inc. raised its holdings in shares of Becton, Dickinson and Company by 71.4% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier’s stock valued at $15,471,000 after acquiring an additional 34,437 shares in the last quarter. Transcend Capital Advisors LLC raised its holdings in shares of Becton, Dickinson and Company by 88.2% in the 3rd quarter. Transcend Capital Advisors LLC now owns 5,794 shares of the medical instruments supplier’s stock valued at $1,084,000 after acquiring an additional 2,715 shares in the last quarter. Belpointe Asset Management LLC purchased a new stake in shares of Becton, Dickinson and Company in the 3rd quarter valued at about $650,000. Finally, Assetmark Inc. raised its holdings in shares of Becton, Dickinson and Company by 49.5% in the 3rd quarter. Assetmark Inc. now owns 225,967 shares of the medical instruments supplier’s stock valued at $42,294,000 after acquiring an additional 74,795 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on BDX shares. Wells Fargo & Company raised their price target on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a report on Friday. Stifel Nicolaus lowered their price target on Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday. Evercore raised their price target on Becton, Dickinson and Company from $180.00 to $190.00 in a report on Thursday. Piper Sandler lowered their price target on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Finally, JPMorgan Chase & Co. reduced their price objective on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 10th. Seven investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Hold” and an average price target of $184.71.

Insider Transactions at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 953 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the transaction, the director directly owned 36,763 shares in the company, valued at $6,713,291.43. This trade represents a 2.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders sold 1,102 shares of company stock worth $198,909. 0.40% of the stock is owned by company insiders.

Key Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Evercore raised its price target on BDX from $180 to $190, signaling continued confidence in the company’s outlook. Evercore target increase
• Positive Sentiment: Wells Fargo lifted its price target to $161 from $157, suggesting modest upside from current levels. Wells Fargo target increase
• Positive Sentiment: The company’s earnings beat, revenue beat, and higher profit guidance are supporting the stock’s rebound after the report. BD second-quarter fiscal 2026 financial results
• Neutral Sentiment: BD also appointed Vitor Roque as chief financial officer, a management change that is not clearly positive or negative for the stock. BD appoints Vitor Roque CFO
• Neutral Sentiment: Stifel lowered its price target to $175 from $215, which is still above the current share price but reflects a more cautious view. Stifel target cut

Becton, Dickinson and Company Price Performance

BDX opened at $149.24 on Friday. The stock’s 50 day simple moving average is $158.49 and its 200 day simple moving average is $181.08. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.94 and a quick ratio of 0.58. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The firm has a market cap of $42.49 billion, a price-to-earnings ratio of 37.78, a PEG ratio of 10.63 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.32% and a net margin of 5.33%.The business had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. During the same period last year, the company earned $3.35 EPS. Becton, Dickinson and Company’s revenue for the quarter was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, analysts predict that Becton, Dickinson and Company will post 12.59 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.8%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 68.52%.

Becton, Dickinson and Company announced that its Board of Directors has authorized a share buyback program on Tuesday, January 27th that allows the company to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to repurchase up to 0% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.